Co-Diagnostics Inc CoPrimers Provide High-Performance Detection of Cancer Mutations in Liquid Biopsy Samples
Co-Diagnostics, Inc. (CODX)
US:NASDAQ Investor Relations:
ir.codiagnostics.com/investor-relations
Company Research
Source: GlobeNewswire
Salt Lake City, UT, July 18, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today favorable results of a study to detect cancer mutations using its patented CoPrimer™ technology, with applications in liquid biopsy and companion diagnostic tests. Unlike invasive and more expensive tissue biopsies, liquid biopsies identify traces of cancer in a simple blood draw. The Company's study, performed on circulating free DNA (cfDNA) reference materials, demonstrated highly specific detection of the ten mutations associated with non-small cell lung cancer (NSCLC), reliably and successfully distinguishing the genes with mutations from those without. The CoPrimer-based polymerase chain reaction (PCR) test was also shown to be highly sensitive, identifying the NSCLC genes at the lowest possible percentage available with the reference material. PCR-based li
Show less
Read more
Impact Snapshot
Event Time:
CODX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CODX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CODX alerts
High impacting Co-Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
CODX
News
- Co-Diagnostics, Inc. (NASDAQ: CODX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.MarketBeat
- Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navigating Revenue Decline and ... [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial ResultsPR Newswire
CODX
Earnings
- 11/7/24 - Beat
CODX
Analyst Actions
- 11/11/24 - HC Wainwright
CODX
Sec Filings
- 11/8/24 - Form 8-K/A
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- CODX's page on the SEC website